Skip to content

Deals

OIS Index Posts a Strong Finish to 2019

OIS Index Posts a Strong Finish to 2019

The OIS Index of ophthalmic stocks made a strong comeback in Q4-2019, following a rough Q3. The index gained 16.2% in Q4, slightly underperforming the NASDAQ Biotechnology Index (+21.1%) but outperforming the overall US stock market as measured by the Russell 3000 Index (+8.6%) and a composite of US medical device stocks (+6.9%). For the…

Read More

OIS Index Outperforms

OIS Index Outperforms

The OIS Index of ophthalmic stocks gained 5.4% in November, following a similar 5.2% gain in October. The index outperformed medical device stocks (+4.3%) and the broader US stock market (+3.6%) but lagged the biotech sector (+11.4%). The largest positive contributor was Adverum Biotechnologies (+50.1%), which continued its steady rebound from a September decline related…

Read More

Bausch, Clearside See Gains Post-Deal

Bausch, Clearside See Gains Post-Deal

When it comes to the stock market, Bausch Health’s has been rising steadily, up 4.1% in the past month, and on November 13 hit a 52-week high; Zacks Equity Research thinks the recent run may continue, and with good reason as the company just partnered with Clearside Biomedical to enter into the suprachoroidal space with…

Read More

Private Financing Trends: Ophthalmology Ranks Tenth

Private Financing Trends: Ophthalmology Ranks Tenth

SAN FRANCISCO, Calif. — Almost $25 billion in venture funds have been raised in just the United States alone over the past 2.5 years to deploy into venture-backed healthcare companies, said Jonathan Norris, managing director at Silicon Valley Bank, during this year’s OIS@AAO conference, and ophthalmology has grabbed the No. 10 spot. Mr. Norris highlighted…

Read More

OIS Index on Positive Upswing

OIS Index Nov. 2019

The OIS Index of ophthalmic stocks gained 5.2% in October, posting its first month of positive performance since June. The index lagged the biotech sector (+7.7%) and outperformed an index of medical device stocks (+0.8%) and the broader US stock market (+2.0%). The largest positive contributor was STAAR Surgical (+27.2%), driven by strong Q3 results.…

Read More

Opthea’s Star Brightens for Stakeholders

Opthea’s Star Brightens for Stakeholders

It’s been a good year for Opthea Ltd., a biotechnology company based in Melbourne, Australia. It’s listed on the Australian Securities Exchange (ASX), trading as OPT. Opthea is a top performer in the OIS Index of ophthalmic biotech and biopharma companies. While the OIS Index was down 12.0% over the 3 months from July through…

Read More

At OIS: Rarities and Thought Provokers

At OIS: Rarities and Thought Provokers

OIS Contributors An eye drop with the potential to fix, albeit temporarily, presbyopia. An artificial endothelial cornea, ready for trial. A neurostimulation device for dry eye in which all 180 trial participants experienced a reduction in symptoms. Two Phase III trials – one on the horizon, for ocular graft versus host designation, the other, already…

Read More

OIS Index Deep in Bear Territory in Q3

OIS Index Deep in Bear Territory in Q3

The OIS Index of ophthalmic stocks posted a miserable Q3 performance, led by the biopharmaceutical stocks in the index. The OIS Index (-12.0%) underperformed the NASDAQ Biotechnology Index (-8.8%), the overall US stock market as measured by the Russell 3000 Index (+0.7%), and a composite of US medical device stocks (+2.7%). Declining stocks in the…

Read More

Retina Treatment Beyond Protocol

Retina Treatment Beyond Protocol

CHICAGO — Optimal treatment of retinal diseases hinges on better understanding in three primary areas, said an expert panel at OIS@ASRS 2019: the disease mechanisms involved; individual patient differences; and the timing of injections. A fourth point involves treatment yet to be developed: A safe, effective, long-term delivery system for anti-VEGF agents. Panel moderator Robert…

Read More

What Has 50 Companies, Four Breakout Sessions, Winning Pitch Winners, and a Keynote Conversation? OIS@AAO 2019

What Has 50 Companies, Four Breakout Sessions, Winning Pitch Winners, and a Keynote Conversation? OIS@AAO 2019

SAN FRANCISCO — Winners of a “Shark Tank” style challenge in cataract/refractive and retina and specialty showcase sessions targeting four themes, including gene and cell therapy and drug delivery, are two of the new wrinkles in this year’s OIS@AAO to be held at the Hilton Union Square here. Fifty companies in all will be presenting…

Read More

5 Factors for Evaluating Investments in the Retina Space

5 Factors for Evaluating Investments in the Retina Space

As noted in a previous installment, innovators in the retina space sometimes utilize ex-US partnerships for financing the expensive process of taking drugs and devices all the way through development. But innovators must consider a number of other critical factors – five to be exact: whether to work with a small or a large investment…

Read More
Scroll To Top